HC Wainwright reissued their buy rating on shares of Immuron Limited – American Depositary Shares (NASDAQ:IMRN) in a report released on Friday. HC Wainwright currently has a $20.00 price target on the stock.
Shares of Immuron Limited – American Depositary Shares (NASDAQ:IMRN) opened at $11.35 on Friday. Immuron Limited – American Depositary Shares has a 1-year low of $4.47 and a 1-year high of $16.70.
ILLEGAL ACTIVITY NOTICE: This article was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://sportsperspectives.com/2018/03/12/immuron-limited-american-depositary-shares-imrn-buy-rating-reiterated-at-hc-wainwright.html.
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.